Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
308 GBX | +2.67% | +6.21% | +8.83% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.83% | 3.2B | |
+31.66% | 699B | |
+25.97% | 571B | |
-4.26% | 364B | |
+18.08% | 326B | |
+2.10% | 286B | |
+14.60% | 236B | |
+4.45% | 198B | |
-11.82% | 194B | |
-4.31% | 154B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED China : , AstraZeneca Drug Savolitinib Wins Conditional Approval in China for Some Lung Cancers